Roivant Sciences Ltd (ROIV) is a Healthcare · Biotechnology company listed on NASDAQ. Price $39.77 (-0.53%), Market cap $20.30B, 52-week low–high $10.62 ~ $29.83.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the tr
Financial statements, price targets, institutional (13F) holdings and related news for Roivant Sciences Ltd are updated in real time on BlackAll Trade.
Roivant Sciences Ltd trades at $39.77 (-0.53%). Real-time quotes and charts are available on BlackAll Trade.
Roivant Sciences Ltd has a market cap of about $20.30B.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include I